Patients Delay Treating Hereditary Angioedema (HAE) Attacks with Currently Available, Injectable, On-demand Therapies

Anna Valeriuela,1 Sally van Kooten,2 Markus Heckmann,2 Sherry Danese,3 Ledia Goga,2 Hilary Longhurst.4

1Department of Allergology, Medical University of Sofia, Sofia, Bulgaria; 2KalVista Pharmaceuticals, Inc.; Cambridge, Massachusetts, USA; 3Outcomes Insights, Agoura Hills, California, USA; 4Department of Immunology, Auckland City Hospital and Department of Medicine, University of Auckland, Auckland, New Zealand

Abstract #000511

Background

- HAE is characterized by recurrent and unpredictable episodes of subcutaneous or submucosal swelling which can affect the abdomen, extremities, genitals, face, and larynx
- Symptoms of an HAE attack can be painful and debilitating, potentially interfering with the ability to conduct daily activities (work, school, social activities)
- WAO/EAACI 2022 updated guidelines recommend that all HAE patients:7
  - consider treating all attacks as early as possible
  - have access to sufficient medication to treat two attacks
  - carry on-demand treatment at all times, regardless of prophylactic therapy
- Although self-administration of on-demand parenteral treatments has enhanced overall HAE attack management, it is known that people living with HAE may delay on-demand treatment administration6,8

Rationale

- This survey evaluated on-demand treatment patterns and patient characteristics associated with longer delays in treatment, as reported by individuals living with HAE

Methods

- People living with HAE were recruited by the US Hereditary Angioedema Association (HAEA) to complete an online survey
- The survey was self-reported, and took respondents approximately 20 minutes to complete
- The survey was completed by 107 individuals between September 6 and October 19, 2022
- Respondents provided consent for their data to be used anonymously or in aggregate
- Analysis was performed using descriptive statistics

Results

Table 2. Survey question and responses

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total (n=107)</th>
<th>Prophylaxis + On-demand (n=54)</th>
<th>On-demand Only (n=53)</th>
<th>More Anxious (n=46)</th>
<th>Less Anxious (n=61)</th>
</tr>
</thead>
<tbody>
<tr>
<td>At first recognition of an HAE attack, do you want to administer on-demand treatment?</td>
<td>% &quot;Yes&quot; 86.0%</td>
<td>81.5%</td>
<td>90.6%</td>
<td>95.7%</td>
<td>78.7%</td>
</tr>
<tr>
<td></td>
<td>% &quot;No&quot; 14.0%</td>
<td>18.5%</td>
<td>9.4%</td>
<td>4.3%</td>
<td>21.3%</td>
</tr>
</tbody>
</table>

Conclusions

- Results highlight that despite most patients recognizing the onset of an HAE attack, the majority of respondents reported waiting to administer on-demand treatment
- Those who are younger or have more anxiety about their current on-demand treatment tend to delay administration of treatment the longest
- More impactful patient-physician dialogue, as well as further advancements in treatment options may help to overcome barriers to timely on-demand treatment and ensure current practice guidelines are followed

References


Disclosures

This study was sponsored by KalVista Pharmaceuticals, Inc. All authors met the ICMJE authorship criteria and had full access to relevant data. The authors had full editorial control of the data presented and provided final approval of all content. Neither honoraria nor payments were made for authorship.

Anna Valeriuela – Speaker/Consultant and/or Honoraria/Meeting sponsorship and/or Clinical Research: Ionis Pharmaceuticals, Pharmingen Group NV, Takada/Shire, Sobi, CSL Behring, Pharma, and KalVista Pharmaceuticals, Inc.
Sally van Kooten – Employee of KalVista Pharmaceuticals, Inc.
Markus Heckmann – Employee of KalVista Pharmaceuticals, Inc.
Sherry Danese – Consultant fees from KalVista Pharmaceuticals, Inc.
Ledia Goga – Employee of KalVista Pharmaceuticals, Inc.
Hilary Longhurst – Honoraria/Travel grants and/or Speaker Bureau and/or Consultant/Clinical Research: BioCryst, CSL Behring, Intella, Pharma, Shire/Takeda, and KalVista Pharmaceuticals

Presented: EAACI 2023 Hybrid Congress, June 9 to 11 in Hamburg, Germany.

Please scan this QR code to view the poster after the congress.